Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis

To study a trend in active sacroiliitis (ASI) in patients with axial spondyloarthritis (axSpA) during different short-term regimens using etoricoxib (ET) 90 mg. Forty patients with axSpA, including 30 with ankylosing spondyloarthritis), and ASI (sacroiliac joint (SIJ) osteitis as evidenced by magnet...

Full description

Saved in:

Bibliographic Details
Published in:	Terapevtic̆eskii arhiv Vol. 86; no. 12; pp. 42 - 47
Main Authors:	Gaidukova, I E, Rebrov, A P, Nam, I F, Kirsanova, N V
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) "Consilium Medicum" Publishing house 01-01-2014
Subjects:	Adolescent Adult ankylosing spondylitis axial spondyloarthritis Cyclooxygenase 2 Inhibitors - administration & dosage Cyclooxygenase 2 Inhibitors - adverse effects Cyclooxygenase 2 Inhibitors - pharmacology etoricoxib Humans Middle Aged non-steroidal anti-inflammatory drugs Osteitis - drug therapy Pyridines - administration & dosage Pyridines - adverse effects Pyridines - pharmacology Sacroiliac Joint - drug effects Sacroiliac Joint - pathology sacroiliitis Sacroiliitis - drug therapy Spondylarthritis - drug therapy Spondylitis, Ankylosing - drug therapy Sulfones - administration & dosage Sulfones - adverse effects Sulfones - pharmacology Treatment Outcome Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To study a trend in active sacroiliitis (ASI) in patients with axial spondyloarthritis (axSpA) during different short-term regimens using etoricoxib (ET) 90 mg. Forty patients with axSpA, including 30 with ankylosing spondyloarthritis), and ASI (sacroiliac joint (SIJ) osteitis as evidenced by magnetic resonance imaging) were examined and then randomized to 2 groups: 1) 20 patients who took ET 90 mg four days or more a week; 2) 20 patients who received ET 90 mg 3 days or less a week. Osteitis was measured in 4 quadrants of each SIJ (0-3 scores). Its main criterion was considered to be a decrease in total osteitis activity (TOA) 12 week later. In all the patients (n = 40), TOA decreased from 6.5 (4; 9) to 2 (0; 5) scores (p < 0.0001). In Group 1 (n = 20), that reduced from 6.5 (4; 8.5) to 0 (0; 3) scores (p < 0.0001). In Group 2 (n = 20), that did from 6.5 (4; 10) to 4 (1; 8) scores (p = 0.49). At 12 weeks, in in Groups 1 and 2, the difference in final TOA achieved no statistical significance (p=0.056). In these groups, there were 19 (95%) and 14 (70%) treatment-responsive patients, respectively. The intake of ET 90 mg for 12-weeks is associated with a reduction in the degree of ASI in patients with axSpA. The use of ET 4 times or more a week is more effective in diminishing osteitis than that of ET 3 days or less.
ISSN:	0040-3660 2309-5342
DOI:	10.17116/terarkh2014861242-47